# 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain

> **NCT05265052** · PHASE2 · NOT_YET_RECRUITING · sponsor: **3D Medicines** · enrollment: 177 (estimated)

## Conditions studied

- Cancer Pain

## Interventions

- **DRUG:** 3D1002 (50 mg)(Phase IIa)
- **DRUG:** 3D1002 (100 mg)(Phase IIa)
- **DRUG:** 3D1002 (150 mg)(Phase IIa)
- **DRUG:** 3D1002 monotherapy (Phase IIb)
- **DRUG:** OxyContin monotherapy (Phase IIb)
- **DRUG:** 3D1002 + OxyContin (Phase IIb)

## Key facts

- **NCT ID:** NCT05265052
- **Lead sponsor:** 3D Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 177 (ESTIMATED)
- **Last updated:** 2026-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265052, "3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05265052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*